IRIS
MAZZASCHI, GIULIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.220
AS - Asia 4.167
EU - Europa 2.666
SA - Sud America 617
AF - Africa 261
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 1
Totale 11.943
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.087
SG - Singapore 1.529
CN - Cina 855
IT - Italia 834
VN - Vietnam 802
BR - Brasile 466
HK - Hong Kong 356
IE - Irlanda 329
SE - Svezia 283
DE - Germania 280
FR - Francia 213
ZA - Sudafrica 169
NL - Olanda 142
IN - India 137
GB - Regno Unito 113
RU - Federazione Russa 99
AT - Austria 84
BD - Bangladesh 76
FI - Finlandia 76
CA - Canada 67
AR - Argentina 59
TR - Turchia 48
KR - Corea 44
MX - Messico 44
IQ - Iraq 42
JP - Giappone 37
ES - Italia 34
PH - Filippine 34
ID - Indonesia 32
CZ - Repubblica Ceca 29
PK - Pakistan 29
PL - Polonia 29
BE - Belgio 28
CI - Costa d'Avorio 28
EC - Ecuador 27
UZ - Uzbekistan 23
UA - Ucraina 22
CO - Colombia 21
TH - Thailandia 21
MA - Marocco 17
VE - Venezuela 16
IR - Iran 13
LT - Lituania 12
TW - Taiwan 12
EG - Egitto 11
TN - Tunisia 11
AU - Australia 10
CL - Cile 10
JO - Giordania 10
LU - Lussemburgo 10
MY - Malesia 10
SA - Arabia Saudita 10
KE - Kenya 9
BG - Bulgaria 7
PY - Paraguay 7
AZ - Azerbaigian 6
KZ - Kazakistan 6
IL - Israele 5
AE - Emirati Arabi Uniti 4
CH - Svizzera 4
EE - Estonia 4
HN - Honduras 4
KH - Cambogia 4
NG - Nigeria 4
OM - Oman 4
BO - Bolivia 3
DK - Danimarca 3
GR - Grecia 3
HU - Ungheria 3
MD - Moldavia 3
MK - Macedonia 3
PA - Panama 3
PE - Perù 3
PS - Palestinian Territory 3
RS - Serbia 3
SY - Repubblica araba siriana 3
TT - Trinidad e Tobago 3
UY - Uruguay 3
AL - Albania 2
AO - Angola 2
BA - Bosnia-Erzegovina 2
BB - Barbados 2
BY - Bielorussia 2
CR - Costa Rica 2
DO - Repubblica Dominicana 2
GY - Guiana 2
JM - Giamaica 2
KG - Kirghizistan 2
LA - Repubblica Popolare Democratica del Laos 2
LB - Libano 2
NO - Norvegia 2
NP - Nepal 2
PT - Portogallo 2
QA - Qatar 2
SN - Senegal 2
BH - Bahrain 1
CD - Congo 1
CG - Congo 1
DZ - Algeria 1
ET - Etiopia 1
Totale 11.926
Salva come PNG Salva come JPEG
Città #
Singapore 891
Ashburn 706
Dallas 495
San Jose 422
Hong Kong 337
Dublin 325
Chandler 313
Santa Clara 260
Ho Chi Minh City 246
Parma 189
Beijing 188
Hanoi 174
Boardman 171
Johannesburg 157
Munich 131
Los Angeles 128
Ann Arbor 126
New York 105
Shanghai 103
Lauterbourg 95
Hefei 94
Bologna 79
Milan 65
Vienna 64
São Paulo 46
Bremen 41
Da Nang 40
Helsinki 40
Moscow 38
Princeton 38
Frankfurt am Main 36
Chicago 35
Columbus 34
Marseille 33
Seoul 32
Dearborn 31
Buffalo 30
Council Bluffs 30
Nuremberg 30
Rome 30
Abidjan 28
Atlanta 28
Haiphong 28
Montreal 28
Nanjing 27
Tokyo 27
Brussels 26
Turku 26
London 23
Verona 23
Chennai 22
West Jordan 22
Denver 21
Orem 21
The Dalles 21
Modena 20
Warsaw 20
Amsterdam 19
Bengaluru 19
Des Moines 18
Guangzhou 17
Tashkent 17
Toronto 17
Baghdad 16
Brno 15
Brooklyn 15
Jakarta 15
Mexico City 15
Pune 15
Rio Saliceto 15
Wilmington 15
Boston 14
Jinan 14
Poplar 14
Lahore 13
Redondo Beach 13
Rio de Janeiro 13
Tianjin 13
Belo Horizonte 12
Biên Hòa 12
Houston 12
Seattle 12
Stockholm 12
Venice 12
Fremont 11
Hải Dương 11
Izmir 11
Amman 10
Düsseldorf 10
Guayaquil 10
Phoenix 10
Reggio Emilia 10
Torrile 10
Trento 10
Brasília 9
Buenos Aires 9
Chongqing 9
Curitiba 9
Istanbul 9
Manchester 9
Totale 7.390
Salva come PNG Salva come JPEG
Nome #
238P Exploring blood immune cell dynamics to unravel the immunomodulatory effect of radiotherapy in NSCLC patients undergoing immune checkpoint inhibitors 217
1328P Dynamic blood immune-inflammatory and radiomic profiling to decode distinct patterns of acquired resistance to immunotherapy in NSCLC patients 214
Validation of a radiomic approach to decipher NSCLC immune microenvironment in surgically resected patients 209
227P Sexual dimorphism in immune profile of early and advanced NSCLC 200
1352P A highly predictive blood-radiomics classifier in advanced NSCLC treated with immunotherapy 198
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. 182
Imatinib mesylate-induced cardiomyopathy involves resident cardiac progenitors 182
Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments 180
MESENCHYMAL STROMAL CELLS ISOLATED FROM DEFINED NSCLC CONTEXTURES REPRODUCE THE IMMUNE SIGNATURE OF THE PARENTAL MICROENVIRONMENT 179
INTEGRATION OF TISSUE PD-1/PD-L1 IMMUNE CHECKPOINT WITH COMPUTED TOMOGRAPHY (CT) BASED TEXTURE ANALYSIS EXHIBITS HIGH PROGNOSTIC IMPACE ON SURGICALLY RESECTED NON SMALL CELL LUNG CANCER (NSCLC) 176
The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC 176
Low PD-1 expression in Cytotoxic CD8+ Tumor infiltrating Lymphocytes Confers an Immune Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value 176
189P The parallel interrogation of tissue and peripheral blood immune features unveils a bidirectional crosstalk with clinical impact on resected NSCLC 175
LONGITUDINAL MONITORING OF RADIOMIC AND BLOOD IMMUNE-INFLAMMATORY DESCRIPTORS AS A NON-INVASIVE APPROACH TO PREDICT ICI EFFICACY IN ADVANCED NSCLC PATIENTS 174
Blood and lymphatic vessels contribute to the impact of the immune microenvironment on clinical outcome in non-small-cell lung cancer 173
17P Dynamic changes of CT-radiomic and systemic immune-inflammatory features predict the response to immune checkpoint inhibitors in advanced NSCLC patients 170
CLINICAL PREDICTORS OF 30-DAY MORTALITY IN HOSPITALIZED PATIENTS WITH LUNG CANCER: A RETROSPECTIVE SINGLE-CENTER OBSERVATIONAL STUDY 167
Dataset on the identification of a prognostic radio-immune signature in surgically resected Non Small Cell Lung Cancer 165
Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 164
The role of blood cholesterol quality in patients with advanced cancer receiving immune checkpoint inhibitors 162
BLOOD AND LYMPHATIC VESSELS CONSTITUTE AN ESSENTIAL COMPONENT OF THE IMMUNE MICROENVIRONMENT AND ITS IMPACT ON NON SMALL CELL LUNG CANCER (NSCLC) CLINICAL OUTCOME 161
Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies 160
2315P Clinical and blood immune-inflammatory profiling to decode different patterns of acquired resistance in immunotherapy treated NSCLC patients 156
1929O Soluble PD-L1 and circulating CD8+PD1+ and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients 153
Integrated MRI–Immune–Genomic Features Enclose a Risk Stratification Model in Patients Affected by Glioblastoma 152
Longitudinal Changes of CT-radiomic and Systemic Inflammatory Features Predict Survival in Advanced Non–Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors 152
Spatial architecture of tumour-infiltrating lymphocytes as a prognostic parameter in resected non-small-cell lung cancer 150
Clinico-Immunological Profile of a 67-Year-Old Woman Affected by HER2-Positive Breast Cancer and Autoimmune Dermatomyositis 149
Intersecting Blood Cytokines With Cholesterol Parameters to Profile Patients With Advanced Solid Tumors Receiving Immune Checkpoint Inhibitors 147
91 Circulating lipid profile as a prognostic factor in patients with advanced solid tumors treated with immune checkpoint inhibitors 145
Integrated CT imaging and tissue immune features disclose a radio-immune signature with high prognostic impact on surgically resected NSCLC 144
Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients 144
Dynamic evolution of blood immune-inflammatory descriptors in advanced non-small cell lung cancer undergoing first-line immunotherapy-based regimens 140
Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study 138
Unraveling the link between cholesterol and immune system in cancer: From biological mechanistic insights to clinical evidence. A narrative review 137
Circulating immune-profile as predictor of outcome in advanced NSCLC patients treated with Nivolumab 137
5P Blood immune-inflammatory dynamic unveils distinctive irAE features in ICI treated NSCLC 133
1061P Static and dynamic tracking of radiomic and immunophenotypic features predicts the benefit of immune checkpoint inhibitors in advanced NSCLC 130
1599P Clinical predictors of 30-day mortality in hospitalized patients with lung cancer: A retrospective single-center observational study 127
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors 125
P1.15-04 Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 124
IMPACT OF THE TISSUE DISTRIBUTION OF SUBPOPULATIONS OF TILS AND PD-L1 EXPRESSION ON THE CLINICAL OUTCOME OF NSCLC 124
SURGICAL SAMPLING IS AN EMERGING ISSUE IN THE ASSESSMENT OF THE IMMUNE CONTEXTURE IN NON SMALL CELL LUNG CANCER (NSCLC) 123
9P Identification of a μCT-based radiomic signature of CD8+ tumour infiltrating lymphocytes in an orthotopic murine model 120
Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab 118
Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy 118
Integrating Red Blood Cell Features and Hemoglobin Levels in Metastatic Renal Cell Carcinoma Patients Treated with Pazopanib or Cabozantinib: An Easily Exploitable Prognostic Score 115
Favorable clinical outcome and response to immunotherapy share a common PD-L1/PD-1 based NSCLC immune contexture 114
The prognostic value of the haemoglobin/red cell distribution width ratio in a cohort of pre-treated patients with renal cell carcinoma receiving nivolumab 113
Detection of EGFR-Activating and T790M Mutations Using Liquid Biopsy in Patients With EGFR-Mutated Non–Small-Cell Lung Cancer Whose Disease Has Progressed During Treatment With First- and Second-Generation Tyrosine Kinase Inhibitors: A Multicenter Real-Life Retrospective Study 112
Upper Tract Urinary Carcinoma: A Unique Immuno-Molecular Entity and a Clinical Challenge in the Current Therapeutic Scenario 111
Advanced CT imaging features reflect distinct tissue immune profiles and exhibit high prognostic impact on NSCLC 108
Successful treatment with selpercatinib after pralsetinib-related pneumonitis and intracranial failure in a patient with RET-rearranged nonsmall cell lung cancer 108
THE ROLE OF BLOOD CHOLESTEROL QUALITY IN PATIENTS WITH ADVANCED CANCER RECEIVING IMMUNE CHECKPOINT INHIBITORS 107
Role of Hb to RDW ratio in metastatic renal cell carcinoma patients treated with first-line immunotherapy combinations 107
7P STK11 and Galectin-3 tissue expression entails a prognostic signature in immunotherapy treated NSCLC patients 107
Nivolumab-Induced Guillain-Barré Syndrome Coupled With Remarkable Disease Response in a Case of Heavily Pretreated Lung Adenocarcinoma 104
First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status 104
Divergent PD-1 expression in tissue and circulating CD8 lymphocytes defines an immune profile predictive of the response to nivolumab in advanced NSCLC 103
Differential impact of lipid profile according to neutrophil-to-lymphocyte ratio status in patients with advanced cancer treated with immunotherapy 102
Immunotherapy and Sonpavde score validation in advanced upper tract urothelial carcinoma: a retrospective study by the Italian Network for Research in Urologic-Oncology 101
Thirty-day mortality in hospitalised patients with lung cancer: incidence and predictors 100
Deciphering the different patterns of acquired resistance in immunotherapy treated NSCLC patients through an integrated clinical and blood immuneinflammatory profiling 100
EP.15B.05 Predictors of 30-Day Mortality after Systemic Therapy in Hospitalized Lung Cancer Patients: A Retrospective Single-Center Observational Study 99
Longitudinal blood immune-inflammatory and radiomic profiling to decode different patterns acquired resistance to immunotherapy in patients with NSCLC 97
NGS detection of gene rearrangements and METexon14 mutations in liquid biopsy of advanced NSCLC patients: A study of two Italian centers 97
Prognostic immunoinflammatory and transcriptomic profiles in patients with pleural mesothelioma undergoing immunotherapy 96
A red blood cell-based score in the prognostication of patients with metastatic RCC of the Meet-URO 15 study 95
Evaluation of PBRM1, PD-L1, CD31, and CD4/CD8 ratio as a predictive signature of response to VEGFR-TKI–based therapy in patients with metastatic renal cell carcinoma (mRCC) with IMDC intermediate prognosis: Results from the APAChE-I Study 93
Dynamic evaluation of circulating mirna profile in egfr‐ mutated nsclc patients treated with egfr‐tkis 93
Prognostic Impact of Blood Lipid Profile in Patients With Advanced Solid Tumors Treated With Immune Checkpoint Inhibitors: A Multicenter Cohort Study 92
Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy 91
Burnout and Oncology: an irreparable paradigm or a manageable condition? Prevention strategies to reduce Burnout in Oncology Health Care Professionals 90
Liquid Biopsy and 18F-FDG PET/CT Derived Parameters as Predictive Factors of Osimertinib Treatment in Advanced EGFR-Mutated NSCLC 89
P57.08 High Performance Radiomic Classifier to Predict the Response to Immunotherapy in Advanced NSCLC 89
External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations 89
Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapy 88
Small Cell Lung Cancer Transformation as a Resistance Mechanism to Osimertinib in Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: Case Report and Literature Review 88
MET alterations as resistance mechanisms of dabrafenib-trametinib in BRAF p.V600E mutated non-small cell lung cancer patient 87
Differentially regulated high-throughput CT imaging features correlate to distinct tumor immune contextures portraying a radiomic signature with prognostic impact on surgically resected NSCLC 86
The radiological appearances of lung cancer treated with immunotherapy: a review 85
Therapeutic Outcomes and Clinical Features of Advanced Non-Small Cell Lung Cancer Carrying KRAS Mutations: A Multicenter Real-life Retrospective Study 85
The distinct prognostic impact of circulating lipid profile according to neutrophil to lymphocyte ratio in patients with advanced solid tumors treated with immune check point inhibitors. 83
Drug-drug interactions (DDIs) in elderly patients with metastatic renal cell carcinoma (mRCC) treated with cabozantinib within the multicenter prospective trial ZEBRA/Meet-URO 9 81
The role of c-met as a biomarker and player in innate and acquired resistance in non-small-cell lung cancer: Two new mutations warrant further studies 80
Abscopal effect as part of treatment of oligometastatic head and neck cancer: A case report 77
Cytoreductive nephrectomy in the era of targeted- And immuno- therapy for metastatic renal cell carcinoma: An elusive issue? A systematic review of the literature 75
Integration of tissue and circulating parameters identifies a favorable immune profile in NSCLC patients treated with nivolumab 69
Can we identify a preferred first-line strategy for sarcomatoid renal cell carcinoma? A network meta-analysis 69
Dissecting the impact of Controlling Nutritional Status (CONUT) score on survival outcomes and immune-inflammatory profiles in patients with advanced NSCLC undergoing first-line immunotherapy 67
Evaluation of PBRM1, PD-L1, CD31 and CD4/CD8 ratio as predictive biomarkers of response to VEGFR-TKI-based therapy in metastatic renal cell carcinoma (mRCC) patients with IMDC intermediate prognosis: Results from the APAChE-I study 67
Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer 66
What Is the Real Impact of Concomitant Antibiotics or Proton Pump Inhibitors on Efficacy of Atezolizumab-Based Regimens in Patients With NSCLC? 65
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort 65
Immune checkpoint inhibitors in hepatocellular cancer patient with congenital haemophilia A 64
Identification of a radio-immune signature with high prognostic value in surgically resected NSCLC 62
Multicenter Observational Study on Metastatic Non-Small Cell Lung Cancer Harboring BRAF Mutations: Focus on Clinical Characteristics and Treatment Outcome of V600E and Non-V600E Subgroups 59
Exploring genetic and immune underpinnings of the sexual dimorphism in tumor response to immune checkpoints inhibitors: A narrative review 57
Genetic, tissue and circulating PD-L1 profiling to predict the response to immuno-checkpoint inhibitors in advanced NSCLC 56
Role of Clock Genes and Circadian Rhythm in Renal Cell Carcinoma: Recent Evidence and Therapeutic Consequences 54
Totale 12.007
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.856
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.856
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202173 0 0 0 0 0 0 0 0 0 17 35 21
2021/2022272 13 13 15 19 5 12 60 10 6 10 21 88
2022/20231.306 121 129 72 109 143 143 38 73 391 7 56 24
2023/2024876 33 60 28 36 110 157 97 36 62 80 49 128
2024/20252.804 92 177 226 197 261 244 183 132 253 271 237 531
2025/20266.215 582 512 983 604 796 374 630 322 930 482 0 0
Totale 12.101